CrunchBase is hiring! Check out our open positions →
Register | Login or Login

Exit

Acquired bySanofi Aventis
Price$500M
Date4/09

General Information

Websitebiparsciences.com
CategoryBioTech
Phone(650) 635-6050
Employees
Founded2002
DescriptionPARP Inhibitors (Cancer Therapeutics)

Offices

Headquarters
1000 Marina Blvd.
Suite 550
Brisbane, CA, 94005
USA

People

Chief Financial Officer
President and Chief Executive Officer
Vice President, Clinical Development
Vice President, Regulatory Affairs
Executive Vice President, Development
Corporate Development and Marketing

Former People

Board Member
Board Member

Funding

Tags

BiPar Sciences

BiPar Sciences Inc. is a Brisbane, CA based developer of PARP inhibitors as cancer therapies. BiPar’s key experimental product is BSI-201, currently in mid-stage trials for advanced breast cancer, ovarian cancer and other tumors.

BiPar has raised around $60 million in VC funding, from firms like Domain Associates, Canaan Partners, Vulcan Capital, PolyTechnos Venture Partners, Asset Management Company, and Quantum Technology Partners. It also has raised venture debt from Lighthouse Capital Partners.

On April 15th, 2009, French drug maker Sanofi-Aventis S.A. announced it was acquiring BiPar Sciences for up to $500 million.

Recent Milestones

Videos

Screenshots

Products

BSI-201

BSI-201, targets PARP, or poly (ADP-ribose) polymerase, a key enzyme involved in DNA repair and cell proliferation. By inhibiting the enzymatic activity of PARP, BSI-201 significantly enhances the anti-tumor effects of chemotherapy and has shown promising safety and efficacy results in patients with solid tumors.

BSI-201 is in Phase 2 clinical studies of patients with triple negative breast cancer, ovarian cancer and other malignancies.

Sources

  1. Sanofi to Buy BiPar Sciences (online.wsj.com) [edit]
  2. BiPar Sciences Raises $13 Million in Series A Financing (biparsciences.com) [edit]
  3. BiPar Sciences Announces $5 Million Financing to Accelerate BSI-201 Clinical Program (biparsciences.com) [edit]
  4. BiPar Sciences Raises $35 Million to Advance Pipeline of Novel PARP Inhibitor Cancer Drug Candidates (biparsciences.com) [edit]
  5. BiPar Sciences Raises $20 Million to Advance Clinical Programs (biparsciences.com) [edit]
Edit This Page
Last Edited 6/19/13

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ยป

Recent Incoming Links

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy